CL2011000237A1 - Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico. - Google Patents

Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico.

Info

Publication number
CL2011000237A1
CL2011000237A1 CL2011000237A CL2011000237A CL2011000237A1 CL 2011000237 A1 CL2011000237 A1 CL 2011000237A1 CL 2011000237 A CL2011000237 A CL 2011000237A CL 2011000237 A CL2011000237 A CL 2011000237A CL 2011000237 A1 CL2011000237 A1 CL 2011000237A1
Authority
CL
Chile
Prior art keywords
epiridine
labeling
pet
derivatives
pharmaceutical composition
Prior art date
Application number
CL2011000237A
Other languages
English (en)
Inventor
Lutz Lehmann
Andrea Thiele
Tobias Henrich
Sonja Vollmer
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CL2011000237A1 publication Critical patent/CL2011000237A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos derivados de 3-piridin-amidas sustituidas; composición farmacéutica; kit farmacéutico; procedimiento de preparación; útiles en el diagnóstico de enfermedades del SNC.
CL2011000237A 2008-08-06 2011-02-04 Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico. CL2011000237A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161903 2008-08-06

Publications (1)

Publication Number Publication Date
CL2011000237A1 true CL2011000237A1 (es) 2011-07-29

Family

ID=41198601

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011000237A CL2011000237A1 (es) 2008-08-06 2011-02-04 Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico.

Country Status (24)

Country Link
US (1) US20110200535A1 (es)
EP (1) EP2321279B1 (es)
JP (1) JP2011529929A (es)
KR (1) KR20110041559A (es)
CN (1) CN102112448B (es)
AR (1) AR073263A1 (es)
AU (1) AU2009278279B2 (es)
BR (1) BRPI0917099A2 (es)
CA (1) CA2733105A1 (es)
CL (1) CL2011000237A1 (es)
CO (1) CO6351715A2 (es)
CR (1) CR20110064A (es)
DO (1) DOP2011000046A (es)
EA (1) EA018650B1 (es)
EC (1) ECSP11010808A (es)
IL (1) IL210597A0 (es)
MX (1) MX2011001406A (es)
NZ (1) NZ590923A (es)
PE (1) PE20110226A1 (es)
SV (1) SV2011003830A (es)
TW (1) TW201010734A (es)
UY (1) UY32037A (es)
WO (2) WO2010015340A1 (es)
ZA (1) ZA201101700B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI549692B (zh) 2006-12-26 2016-09-21 藍瑟斯醫學影像公司 使心臟神經分布顯像之配位體
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment
GB0904715D0 (en) 2009-03-19 2009-05-06 Ge Healthcare Ltd Aryloxyanilide derivataives
WO2011110488A1 (en) * 2010-03-09 2011-09-15 Bayer Pharma Aktiengesellschaft A novel pet imaging agent of amyloid plaques and its precursor
KR102136503B1 (ko) * 2010-05-11 2020-07-21 랜티우스 메디컬 이메징, 인크. 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
CN103180318B (zh) 2010-05-14 2017-05-10 达那-法伯癌症研究所 雄性避孕组合物以及使用方法
BR122014024883A2 (pt) 2010-05-14 2019-08-20 Dana-Farber Cancer Institute, Inc. Compostos no tratamento de neoplasia
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
BR122019017259B1 (pt) 2011-09-09 2022-05-10 Lantheus Medical Imaging, Inc Compostos úteis como agentes de imageamento, composições que os compreende, métodos, e uso de agentes de imageamento
WO2015013635A2 (en) 2013-07-25 2015-01-29 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
WO2015117087A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
CN106456653A (zh) 2014-02-28 2017-02-22 腾沙治疗公司 高胰岛素血症相关病症的治疗
CA2955077A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
BR112017002369A2 (pt) 2014-08-08 2017-12-05 Dana Farber Cancer Inst Inc derivados de diazepana e usos dos mesmos
EA033325B1 (ru) 2014-10-27 2019-09-30 Тэнша Терапеутикс, Инк. Ингибиторы бромодомена
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044792A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazoldiazepines and uses thereof
BR112018004618A2 (pt) 2015-09-11 2018-09-25 Dana-Farber Cancer Institute, Inc. ciano tienotriazoldiazepinas e usos das mesmas
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
CN105541931B (zh) * 2016-01-07 2018-08-17 江西师范大学 一种氟代糖苷衍生物及其制备方法
EP3717025B1 (en) * 2017-12-01 2021-11-03 UCB Biopharma SRL Imaging agents
CN111039853B (zh) * 2019-12-26 2023-02-14 安徽大学 一种可用于光声成像和光热治疗的铁配合物及其制备方法和用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69809063T2 (de) * 1997-08-04 2003-06-12 Taisho Pharmaceutical Co Ltd Aryloxyanilin-derivate
JP2000001476A (ja) * 1998-06-15 2000-01-07 Taisho Pharmaceut Co Ltd アリールオキシ含窒素アリールアミン誘導体
JP2004231647A (ja) * 2003-01-10 2004-08-19 Natl Inst Of Radiological Sciences フェニルオキシアニリン誘導体
US6870069B2 (en) * 2003-01-10 2005-03-22 National Institute Of Radiological Sciences Phenyloxyaniline derivatives
GB0329716D0 (en) * 2003-12-23 2004-01-28 Amersham Plc Radical trap
WO2007010534A2 (en) * 2005-07-19 2007-01-25 Spectrum Dynamics Llc Imaging protocols
GB0407952D0 (en) * 2004-04-08 2004-05-12 Amersham Plc Fluoridation method
DE102005055524B4 (de) * 2005-11-22 2013-02-07 BEGO Bremer Goldschlägerei Wilh. Herbst GmbH & Co. KG Verfahren, Vorrichtung und System zur Herstellung eines keramischen Formkörpers
WO2007060517A1 (en) * 2005-11-22 2007-05-31 Ge Healthcare Limited 18f-labeled daa analogues and methods of labeling these analogues as positron emission tomography (pet) tracers for imaging peripheral benzodiazepine receptors
GB0525949D0 (en) * 2005-12-21 2006-02-01 Hammersmith Imanet Ltd Pet radiotracers
MX2008016344A (es) * 2006-06-21 2009-02-12 Ge Healthcare Ltd Productos radiofarmaceuticos.
WO2010015340A1 (en) * 2008-08-06 2010-02-11 Bayer Schering Pharma Aktiengesellschaft Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment

Also Published As

Publication number Publication date
MX2011001406A (es) 2011-03-21
NZ590923A (en) 2012-12-21
UY32037A (es) 2010-03-26
TW201010734A (en) 2010-03-16
CR20110064A (es) 2011-03-30
CA2733105A1 (en) 2010-02-11
CN102112448A (zh) 2011-06-29
AU2009278279B2 (en) 2014-04-17
IL210597A0 (en) 2011-03-31
AU2009278279A1 (en) 2010-02-11
WO2010015340A1 (en) 2010-02-11
EA201100301A1 (ru) 2011-12-30
CN102112448B (zh) 2014-08-06
KR20110041559A (ko) 2011-04-21
EA018650B1 (ru) 2013-09-30
BRPI0917099A2 (pt) 2016-02-16
PE20110226A1 (es) 2011-04-01
JP2011529929A (ja) 2011-12-15
US20110200535A1 (en) 2011-08-18
SV2011003830A (es) 2011-05-20
CO6351715A2 (es) 2011-12-20
WO2010015387A1 (en) 2010-02-11
EP2321279B1 (en) 2014-07-02
AR073263A1 (es) 2010-10-28
EP2321279A1 (en) 2011-05-18
ZA201101700B (en) 2014-08-27
DOP2011000046A (es) 2011-02-28
ECSP11010808A (es) 2011-03-31

Similar Documents

Publication Publication Date Title
CL2011000237A1 (es) Compuestos adecuados para marcar o ya marcados con 18f , derivados d epiridina, ligando del receptor periferico de benzodiazepina para el diagnostico por imagenes mediante topografia de emisión de positrones (pet); composición farmaceutica; kit farmaceutico.
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
GEP20237479B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CL2009000161A1 (es) Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
WO2008098112A3 (en) Positron emission tomography imaging method
MX2010010407A (es) Derivados de 4-aminociclohexanos sustituidos.
JO3408B1 (ar) مركبات بترين سلفون اميد ثيازول و أوكسازول
BRPI0711481A8 (pt) derivados radiomarcados de dihidrotetrabenzeno e seu uso como agente de imagens
EA201170198A1 (ru) Фармацевтические композиции, содержащие лиганды рецептора дофамина
ECSP13012788A (es) Derivados de biciclo[3,2,1]octilamida y sus usos
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
CY1112095T1 (el) Υποκατεστημενα σπειροκυκλικα παραγωγα κυκλοεξανιου
TW200800967A (en) Benzimidazole thiophene compounds
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
MX2009004686A (es) Acido l-glutamico marcado con [f-18], l-glutamina marcada con [f-18], sus derivados y su uso, asi como procedimientos para su preparacion.
DE602006012694D1 (de) Benzimidazolthiophenverbindungen als plk-modulatoren
WO2009052970A3 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
CL2009000281A1 (es) Compuestos derivados de 5,6-dihidro-pirrolo-[2,1-a]-isoquinolinas y pirrolo-[2,1-a]-isoquinolinas; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamaiento de trastornos de la fertilidad.
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CL2014000246A1 (es) Compuestos derivados fenil-3-aza-biciclo[3.1.0]hex-3-il-metanonas, inhibidores del transportador de glicina (glyt1); composicion farmaceutica que los contiene; combinacion farmaceutica; y su uso en el tratamiento de alzheimer, alteraciones cognitivas en esquizofrenia, psicosis, trastornos psiquiatricos, entre otros
SG194761A1 (en) Radiolabeled amino acids for diagnostic imaging
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
BRPI0821450A2 (pt) Derivado (aza) indol substituído na posição 5, proceso para a preparação do mesmo, composto intermediário, e, composição farmacêutica.
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.